B L Hua
Concise Prescribing Info
Major depressive episodes, panic disorder w/ or w/o agoraphobia, social anxiety disorder  (social phobia), generalized anxiety disorder, obsessive-compulsive disorder.
Dosage/Direction for Use
Major depressive episodes, obsessive-compulsive disorder 10 mg or 10 drops once daily. May be increased to a max of 20 mg or 20 drops. Panic disorder w/ or w/o agoraphobia Initially 5 mg or 5 drops on the 1st wk, then increase dose to 10 mg or 10 drops up to a max of 20 mg or 20 drops daily. Social anxiety disorder & generalised anxiety disorder 10 mg or 10 drops once daily. May be increased up to a max of 20 mg or 20 drops daily. Elderly >65 yr Initially ½ the usual recommended dose. Consider lower max dose. Reduced hepatic function/poor CYP2C19 metabolisers Initially 5 mg or 5 drops daily for the first 2 wk. May be increased to 10 mg or 10 drops daily.
May be taken with or without food: Oral Drops: Mix w/ water, orange or apple juice.
Hypersensitivity. Concomitant treatment w/ nonselective/irreversible MAOI therapy & pimozide.
Special Precautions
Monitor for the appearance of suicidal symptoms (especially in the 1st few wk of treatment). Paradoxical anxiety. Discontinue treatment if seizures, manic phase occurs or if there is increase in seizure frequency. Closely monitor patients w/ unstable & controlled epilepsy. History of hypomania/mania. May alter glycaemic control. History of suicide-related events or those exhibiting a significant degree of suicidal ideation prior to treatment. Development of akathisia/psychomotor restlessness. Patients at risk of hyponatraemia, eg, elderly & patients w/ cirrhosis; w/ known bleeding tendencies. Concomitant use w/ drugs that may cause hyponatraemia; SSRIs particularly w/ anticoagulants; drugs that affect platelet functions (eg, atypical antipsychotics & phenothiazines, TCAs, acetylsalicylic acid, NSAIDs, ticlopidine & dipyridamole), serotonergic effects (eg, sumatriptan or other triptans, tramadol & tryptophan), St. John's wort; electroconvulsive therapy, MAO-A inhibitors. Avoid abrupt w/drawal. Severely reduced renal function (CrCl <30 mL/min). May impair the ability to drive or operate machinery. Pregnancy & lactation. Childn & adolescents <18 yr.
Adverse Reactions
Nausea. Decreased/increased appetite, increased wt; anxiety, restlessness, abnormal dreams, decreased libido, anorgasmia in females; insomnia, somnolence, dizziness, paraesthesia, tremor; sinusitis, yawning; diarrhoea, constipation, vomiting, dry mouth; increased sweating; arthralgia, myalgia; ejaculation disorder & impotence in males; fatigue, pyrexia.
Drug Interactions
Non-selective, irreversible MAOIs. May increase QTc interval w/ pimozide. Risk of serotonin syndrome w/ reversible, selective MAO-A inhibitor (moclobemide), selegiline, serotonergic products (eg, tramadol, sumatriptan & other triptans). May lower seizure threshold w/ antidepressants (eg, tricyclics, SSRIs), neuroleptics (phenothiazines, thioxanthenes, butyrophenones), mefloquine, bupropion & tramadol. May enhance effects w/ lithium or tryptophan. Increased incidence of adverse reactions w/ St. John's wort (Hypericum perforatum). May alter anticoagulant effects w/ oral anticoagulants. Increased bleeding tendencies w/ NSAIDs. Alcohol. Increased plasma conc w/ omeprazole & cimetidine, CYP2C19 inhibitors (eg, omeprazole, fluoxetine, fluvoxamine, lansoprazole, ticlopidine). Drugs that metabolize CYP2D6 enzyme, have narrow therapeutic index eg, flecainide, propafenone & metoprolol or CNS-acting drugs eg, antidepressants (desipramine, clomipramine & nortryptyline) or antipsychotic (risperidone, thioridazine & haloperidol).
MIMS Class
ATC Classification
N06AB10 - escitalopram ; Belongs to the class of selective serotonin reuptake inhibitors. Used in the management of depression.
Lexapro FC tab 15 mg
Lexapro oral drops 20 mg/mL
15 mL x 1's
Lexapro FC tab 10 mg
Lexapro FC tab 20 mg
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in